Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in three upcoming virtual investor conferences:
Morgan Stanley Virtual 19th Annual Global Healthcare Conference
Fireside Chat Date: Friday, September 10, 2021
Time: 2:00 PM ET
H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13th through Wednesday, September 15th, 2021
Oppenheimer’s Virtual Fall Healthcare Life Sciences & MedTech Summit
Presentation Date: Wednesday, September 22, 2021
Time: 3:45 PM ET
The fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference and presentation at the Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit will be webcast live. A pre-recorded webcast of the presentation at the H.C. Wainwright 23rd Annual Global Investment Conference will be made available on Monday, September 13, 2021, at 7:00 AM ET. All of the webcasts can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of each webcast will also be available.
About Vor Biopharma
Vor Biopharma is a cell and genome engineering company that aims to transform the lives of cancer patients by pioneering an engineered hematopoietic stem cell (eHSC) therapeutic platform that unlocks the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancer cells while sparing healthy cells.
Contacts:
Investors:
Chris Brinzey
Westwicke, an ICR Company
+1 339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Rebecca Spalding
Ten Bridge Communications
+1 646-509-3831
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.33 |
Daily Change: | -0.03 -2.21 |
Daily Volume: | 359,472 |
Market Cap: | US$165.640M |
January 08, 2025 December 27, 2024 September 05, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load